Leerink Partnrs Estimates Zoetis’ FY2024 Earnings (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – Stock analysts at Leerink Partnrs issued their FY2024 EPS estimates for shares of Zoetis in a research note issued to investors on Monday, December 2nd. Leerink Partnrs analyst D. Clark forecasts that the company will post earnings of $5.96 per share for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. Leerink Partnrs also issued estimates for Zoetis’ Q4 2024 earnings at $1.44 EPS, Q1 2025 earnings at $1.50 EPS, Q2 2025 earnings at $1.68 EPS, Q3 2025 earnings at $1.72 EPS, Q4 2025 earnings at $1.57 EPS, FY2025 earnings at $6.48 EPS, FY2026 earnings at $7.15 EPS, FY2027 earnings at $7.84 EPS and FY2028 earnings at $8.49 EPS.

A number of other analysts have also issued reports on ZTS. BTIG Research boosted their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus upped their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. increased their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Leerink Partners assumed coverage on Zoetis in a report on Monday. They issued an “outperform” rating and a $215.00 price objective for the company. Finally, Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Eleven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $220.80.

Zoetis Trading Up 0.1 %

NYSE ZTS opened at $176.94 on Wednesday. The firm’s 50-day moving average is $183.16 and its two-hundred day moving average is $181.01. Zoetis has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The stock has a market capitalization of $79.83 billion, a P/E ratio of 33.26, a PEG ratio of 2.71 and a beta of 0.89.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter in the previous year, the company posted $1.36 EPS. The company’s revenue was up 11.6% compared to the same quarter last year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st were given a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend was Thursday, October 31st. Zoetis’s payout ratio is 32.52%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Simplify Asset Management Inc. purchased a new position in shares of Zoetis in the third quarter valued at $11,684,000. Bank Pictet & Cie Asia Ltd. increased its position in Zoetis by 41.0% during the 2nd quarter. Bank Pictet & Cie Asia Ltd. now owns 37,500 shares of the company’s stock worth $6,501,000 after purchasing an additional 10,900 shares in the last quarter. Swedbank AB increased its position in Zoetis by 56.2% during the 2nd quarter. Swedbank AB now owns 1,946,277 shares of the company’s stock worth $337,407,000 after purchasing an additional 700,398 shares in the last quarter. B&L Asset Management LLC purchased a new stake in Zoetis during the 3rd quarter worth about $563,000. Finally, Raymond James & Associates increased its position in Zoetis by 6.1% during the 2nd quarter. Raymond James & Associates now owns 794,419 shares of the company’s stock worth $137,720,000 after purchasing an additional 45,597 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.